Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT 1 R) blockers, current …

After its discovery in the early 1980s, the natriuretic peptide (NP) system has been
extensively characterized and its potential influence in the development and progression of …

This article provides a contemporary review and a new perspective on the role of neprilysin
inhibition in heart failure (HF) in the context of recent clinical trials and addresses potential …

The discovery in the early 1980s of atrial natriuretic peptide, a circulating peptide with
natriuretic/diuretic and vasorelaxant properties was greeted with excitement since the …

Neprilysin has a major role in both the generation and degradation of bioactive peptides.
LCZ696 (valsartan/sacubitril, Entresto), the first of the new ARNI (dual-acting angiotensin …

Background—Neutral endopeptidase (NEP) degrades vasoactive peptides, including the
natriuretic peptides, angiotensin II, and endothelin-1. Systemic inhibition of NEP does not …

Racecadotril, via its active metabolite thiorphan, is an inhibitor of the enzyme neutral
endopeptidase (NEP, EC 3.4. 24.11), thereby increasing exposure to NEP substrates …

The enormous benefits of inhibition of ACE demonstrate that manipulation of the metabolism
of peptide hormones is a valuable therapeutic strategy for cardiovascular disease. Recent …

Angiotensin-converting enzyme and neutral endopeptidase (EC 3.4. 24.11; neprilysin) are
metallopeptidases present on the endothelium that metabolize bradykinin. Inhibitors of …

It has been known since the 1990s that long-term morbidity and mortality is improved in
patients with heart failure with reduced ejection fraction (HFrEF) by treatments that target the …